Ovarian adenocarcinoma
diseaseOn this page
Also known as adenocarcinoma of ovaryadenocarcinoma of the ovaryovary adenocarcinoma
Summary
Ovarian adenocarcinoma (MONDO:0002752) is a disease (an umbrella term covering 7 Mondo subtypes) and 17 clinical trials. Top therapeutic interventions include ipilimumab, emactuzumab, and oregovomab. A subtype of adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Umbrella term: 7 Mondo subtypes
- Clinical trials: 17
Clinical features
Epidemiology
Prevalence records
24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 5.97 | Europe | Validated |
| Annual incidence | 1-9 / 100 000 | 5.635 | Austria | Validated |
| Annual incidence | 1-9 / 100 000 | 6.773 | Belgium | Validated |
| Annual incidence | 1-9 / 100 000 | 6.162 | Bulgaria | Validated |
| Annual incidence | 1-9 / 100 000 | 6.103 | Croatia | Validated |
| Annual incidence | 1-9 / 100 000 | 7.229 | Czech Republic | Validated |
| Annual incidence | 1-9 / 100 000 | 6.881 | Estonia | Validated |
| Annual incidence | 1-9 / 100 000 | 5.973 | Finland | Validated |
| Annual incidence | 1-9 / 100 000 | 6.593 | Germany | Validated |
| Annual incidence | 1-9 / 100 000 | 4.09 | Iceland | Validated |
| Annual incidence | 1-9 / 100 000 | 5.079 | Ireland | Validated |
| Annual incidence | 1-9 / 100 000 | 5.518 | Italy | Validated |
| Annual incidence | 1-9 / 100 000 | 8.353 | Latvia | Validated |
| Annual incidence | 1-9 / 100 000 | 7.79 | Lithuania | Validated |
| Annual incidence | 1-9 / 100 000 | 5.653 | Malta | Validated |
| Annual incidence | 1-9 / 100 000 | 7.116 | Norway | Validated |
| Annual incidence | 1-9 / 100 000 | 5.698 | Poland | Validated |
| Annual incidence | 1-9 / 100 000 | 2.834 | Portugal | Validated |
| Annual incidence | 1-9 / 100 000 | 5.519 | Slovakia | Validated |
| Annual incidence | 1-9 / 100 000 | 6.575 | Slovenia | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ovarian adenocarcinoma |
| Mondo ID | MONDO:0002752 |
| EFO | EFO:0006460 |
| Orphanet | 213504 |
| DOID | DOID:3713 |
| NCIT | C7700 |
| UMLS | C0948216 |
| MedGen | 181757 |
| GARD | 0020466 |
| MedDRA | 10051938 |
| Anatomy (UBERON) | UBERON:0000992 |
| Is cancer (heuristic) | no |
Also known as: adenocarcinoma of ovary · adenocarcinoma of the ovary · ovarian adenocarcinoma · ovary adenocarcinoma
Data availability: 47 cell lines.
Disease family
This is a subtype of adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › ovarian adenocarcinoma
Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma
Subtypes (7): ovarian cystadenocarcinoma, rete ovarii adenocarcinoma, Krukenberg carcinoma, ovarian serous adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 17.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE1/PHASE2 | 4 |
| PHASE2 | 4 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT05335993 | PHASE2 | ACTIVE_NOT_RECRUITING | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. |
| NCT05451849 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer |
| NCT00660101 | PHASE1/PHASE2 | UNKNOWN | Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer |
| NCT02923739 | PHASE2 | TERMINATED | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT03365791 | PHASE2 | COMPLETED | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies |
| NCT05001282 | PHASE1/PHASE2 | TERMINATED | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) |
| NCT06393751 | PHASE1/PHASE2 | WITHDRAWN | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer |
| NCT00585845 | PHASE1 | TERMINATED | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment |
| NCT02217956 | PHASE1 | COMPLETED | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma |
| NCT03608618 | PHASE1 | TERMINATED | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma |
| NCT07100288 | Not specified | RECRUITING | Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer |
| NCT07429487 | Not specified | NOT_YET_RECRUITING | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer |
| NCT00899093 | Not specified | TERMINATED | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy |
| NCT03641287 | Not specified | TERMINATED | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors |
| NCT04248231 | Not specified | COMPLETED | CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma |
| NCT06599749 | Not specified | COMPLETED | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| IPILIMUMAB | 4 | 1 |
| EMACTUZUMAB | 3 | 1 |
| OREGOVOMAB | 3 | 1 |
| SPARTALIZUMAB | 3 | 1 |
| IERAMILIMAB | 2 | 1 |
| ASTX-660 | 1 | 1 |
| PASIFOLATE EXATECAN | 1 | 1 |
Related Atlas pages
- Drugs: Ipilimumab, Emactuzumab, Oregovomab, Spartalizumab